Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 30;18(3):431–445. doi: 10.1093/ecco-jcc/jjad166

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Baseline expression associated with primary response. [A] Volcano plots of differential gene expression between responders [PR] and non-responders [PNR] at week 0: for infliximab [IFX], adalimumab [ADA], or with drug subgroups pooled. Annotated genes show significant associations from this study and previously reported associations from the literature in both blood and gut biopsies. Dashed line shows significance threshold at FDR = 0.05. [B] Top gene modules differentially expressed between PR and PNR at week 0. Columns correspond to results for IFX, ADA, difference between IFX and ADA [IFX − ADA, i.e. the drug-by-response interaction], and pooled drug analyses. The top 30 modules ranked by minimum FDR in any column are shown. Dashed lines show significance thresholds at FDR = 0.05.